CYP19A1 and neoplasm: After 7 days, median in vitro tumour aromatase activity was 89% lower than in matched, control tumour specimens; similarly, median tumour levels of E1 and E2 in treated patients were 64 and 80% lower than in controls, respectively (de Jong et al, 1997).